Publications by authors named "Dimitra Stergianou"
Article Synopsis
- Biological therapy for hidradenitis suppurativa (HS) was previously limited to adalimumab, but not all patients respond, leading to a demand for alternative treatments.
- The IL-17A inhibitor secukinumab has recently been FDA-approved as a new option for HS, targeting the IL-17A pathway.
- Clinical trials show that secukinumab is effective with a favorable safety profile, although more long-term data is needed, especially for patients with inflammatory bowel disease.
Article Synopsis
- * Results showed that patients carrying a common genetic variant (GGG haplotype) had a significantly better response to ADA after 12 weeks compared to those with less common SNPs, with response rates of 71.8% vs. 50.0%.
- * The findings suggest that those with minor SNP haplotypes had a lower improvement in certain measures of disease severity, indicating that genetic makeup could influence treatment outcomes and should be considered in clinical decisions.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
J Am Acad Dermatol
August 2021
Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin.
Article Synopsis
- The study investigates the connection between nasal carriage of Staphylococcus aureus (S. aureus) and flare-ups in patients with hidradenitis suppurativa (HS) undergoing treatment with adalimumab (ADA), the only FDA-approved biologic for HS.
- Among 39 patients, those who experienced flare-ups had a higher incidence of nasal S. aureus carriage compared to those with a successful treatment response, indicating a potential link between the bacteria and treatment failure.
- The findings suggest that S. aureus may contribute to the deterioration of response to ADA in HS patients, and further studies are needed to validate these results on a larger scale.
: Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disorder that affects regions rich in apocrine glands. Although the etiology of HS is not clear, inflammatory cytokines, like tumor necrosis factor (TNF)-α, participate in pathogenesis. Adalimumab (ADA), a human IgG1 monoclonal antibody that selectively targets TNFα, is the only EMA/FDA-approved biologic agent available for the therapy of moderate-to-severe HS.
View Article and Find Full Text PDF